Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Micro Sensors, Maven Technologies, Monsanto Technologies, Council of Scientific and Industrial Research


Clinical Micro Sensors of Pasadena, Calif., has received US Patent No. 6,833,267, “Tissue collection devices containing biosensors.” The patent covers tissue-collection devices comprising biosensors that can be used for the detection of target analytes, such as nucleic acids and proteins, including antibodies and enzymes.

Maven Technologies of Los Angeles has received US Patent No. 6,833,920, “Apparatus and method for imaging.” The patent covers an apparatus for acquiring an image of a specimen comprising a cassette that has an optical portion holding a specimen array on a TIR surface. The apparatus has a polarized light-beam source and a processing polarization-sensitive portion to image the spatially distributed charges in polarization of the specimen array. In one form, the array optical portion comprises a transparent slide having a bottom surface with first and second gratings located to direct polarized light to the TIR surface and to direct light reflected by that (TIR) surface to an imager, respectively. The apparatus may include a flow cell integral with the optical portion as well as means for selecting the direction and wavelength of the polarized light.

Monsanto Technologies of St. Louis has received US Patent No. 6,833,447, “Mycococcus xanthus genome sequences and uses thereof.” The patent relates to nucleic acid sequences from the bacterium, Mycococcus xanthus and, in particular, to genomic DNA sequences. The invention encompasses nucleic acid molecules present in non-coding regions as well as nucleic acid molecules that encode proteins and fragments of proteins. In addition, proteins and fragments of proteins so encoded and antibodies capable of binding the proteins are encompassed by the present invention. The invention also encompasses oligonucleotides including primers, e.g., useful for amplifying nucleic acid molecules, and collections of nucleic acid molecules and oligonucleotides, e.g., in microarrays. The invention also provides constructs and transgenic cells and organisms comprising nucleic acid molecules of the invention. The invention also relates to methods of using the disclosed nucleic acid molecules, oligonucleotides, proteins, fragments of proteins, and antibodies, for example, for gene identification and analysis, and preparation of constructs and transgenic cells and organisms.

Council of Scientific and Industrial Research of New Delhi, India, has received US Patent No. 6,833,162, “Colored nanolithography on glass and plastic substrates.” The patent covers a process for generating colored nanolithography patterns of parallel lines or cross-pattern lines on a glass or plastic substrate. The process consists of pressing a polycarbonate or aluminium mold obtained from a compact disk on a glass or plastic surface inked with a permanent marker ink for one or more times to create lithographic patterns of parallel colored lines or cross-pattern lines. Also, the present invention provides a method for generating colored nanolithography patterns of parallel lines or cross-pattern lines on a glass or plastic substrate having dried ink. That method consists of keeping the plastic or glass substrate having the dried ink in a chamber containing ethanol or toluene for about 10 seconds, followed by pressing the polycarbonate or aluminium mold obtained from a compact disk on the glass or plastic surface to generate the pattern.


The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.